Clinical trial
Romidepsin in Treating Patients With Relapsed Small Cell Lung Cancer
NCT00086827 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00086827 |
|---|---|
| Title | Romidepsin in Treating Patients With Relapsed Small Cell Lung Cancer |
| Official title | A Phase II Study of Single Agent Depsipeptide (FK228) (NSC 630176; IND 51,810) in Relapsed Small Cell Lung Cancer |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Recurrent Small Cell Lung Cancer |
| Intervention type | Drug, Other |
| Interventions | romidepsin, laboratory biomarker analysis |
| Enrollment | 36 |
| Start date | May 1, 2004 |
| Primary completion | Nov 1, 2006 |
| First posted | Jul 12, 2004 |
| Last update posted | Apr 10, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: